Sector News

Siemens begins shipping coronavirus antibody tests with goal of 50M per month

May 28, 2020
Life sciences

While aiming to double its manufacturing capacity to more than 50 million blood tests per month, Siemens Healthineers has begun shipping its COVID-19 serology kits internationally, for use on about 20,000 analyzer systems installed worldwide.

The company recently received a CE mark for its IgM and IgG antibody test, designed to run on its high-throughput Advia Centaur and Atellica systems—the latter capable of running up to 440 tests per hour. The kit is currently being reviewed by the FDA for emergency use in the U.S.

Siemens plans to increase production at its sites in Walpole, Massachusetts, and Newark, Delaware, and said it expects to hit the 50-million test target in June.

The company also aims to ship more than 2.5 million molecular, PCR-based coronavirus tests each month, which received an FDA authorization early this month and a CE mark in late April. According to analysts at Bernstein, the company has already sold 500,000 tests in Europe.

Siemens described its total antibody test’s performance as 100% sensitivity and 99.8% specificity—including in detecting the neutralizing antibodies that connect to and block the novel coronavirus’s spike protein, which allows it to enter and infect cells.

“Not all antibody tests are created equal,” Siemens’ president of laboratory diagnostics, Deepak Nath, said in a statement. “A high-quality test that targets the right protein and is highly scalable is essential for antibody testing to help ensure we effectively manage the threat of COVID-19.”

“Siemens Healthineers sought to provide a highly accurate antibody test that could reach millions of people to address the current need for identifying immune response, and also for delivering long-term value as we look toward immunity and vaccination,” Nath added.

The company is also developing similar tests for its Dimension Vista and EXL systems, as well as a specific IgG test to meet different clinical needs.

By: Conor Hale

Source: Fierce Biotech

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach